PI3K and Covid-19

https://www.demiurge.technology/blog/demiurge-ai-discovers-pi3k-inhibitors-as-a-novel-candidate-treatment

Demiurge AI Discovers PI3K inhibitors as a Novel Candidate Treatment Selective for 2019 Novel Coronavirus (COVID-19)

2020-02-14T01:13:52.664-08:SWITZERLAND, FRIDAY, FEBRUARY 14, 2020 11:30 AM

Demiurge is responding to the outbreak of 2019 novel coronavirus (COVID-19) through the appropriate use of our AI platform of discovering novel therapeutic solutions and predicting clinical trial outcomes.

After deep analysis of published studies and data on COVID-19 against our precise broad-spectrum virology models, we hereby officially announce the discovery of phosphoinositide 3-kinase inhibitors (PI3K inhibitors) that can be potentially repurposed into an optimally effective and safe therapeutic solution selectively against COVID-19, though PI3K inhibitors may not be equally effective or safe against SARS coronavirus or MERS coronavirus.

PI3K inhibitors have extensively studied mechanisms of action and have been actively investigated as anticancer treatments. Some PI3K inhibitors (e.g. Idelalisib, Copanlisib, Duvelisib, and Alpelisib) have been approved for various lymphomas. More PI3K inhibitors (e.g. Taselisib, Buparlisib, Umbralisib and Voxtalisib) have entered into late-stage human clinical trials for a broader spectrum of cancers.

The antiviral potential of PI3K inhibitors has been implied in the literature but remaining underexplored in both academia and industry due to the complexity of the underlying biology beyond the reach of conventional approaches. By harnessing the complementary strengths of machine intelligence and human intelligence, we have brought missed data and mislabelled data to a minimum in our investigation of the commonly implicated pathways in both anticancer and antiviral settings, and identified PI3K inhibitors as a potential match to the epidemiological characteristics, transmission dynamics, clinical features, and biological properties of COVID-19.

In endemic/pandemic settings, public interest in treatment availability and commercial interest in marketing exclusivity are usually misaligned, but we have no doubt that public interest must be prioritized because lives matter above all else.

We have thus chosen to announce this discovery to the public first without any delay in either applying for patent protection in secret or working with biopharmaceutical companies in private, so as to waive commercial interests once for all and to speed up cross-border concerted efforts to conduct human clinical trials of PI3K inhibitors for the benefits of millions of families that have been affected by COVID-19.